Altered NMDA receptor expression in renal toxicity: Protection with a receptor antagonist  by Leung, Jocelyn C. et al.
Kidney International, Vol. 66 (2004), pp. 167–176
Altered NMDA receptor expression in renal toxicity: Protection
with a receptor antagonist
JOCELYN C. LEUNG,1 TARA MARPHIS,1 RANDALL D. CRAVER, and DOUGLAS M. SILVERSTEIN
Department of Pediatrics, Division of Neonatology and Division of Nephrology, Louisiana State University Health Sciences Center,
New Orleans, Louisiana; and Department of Pathology Louisiana State University Health Sciences Center, New Orleans, Louisiana
Altered NMDA receptor expression in renal toxicity: Protec-
tion with a receptor antagonist.
Background. The N-methyl-D-aspartate (NMDA) receptor
is expressed in the kidney. The receptor plays a major role in
gentamicin ototoxicity. We assessed the role of the renal NMDA
receptor subunits NR1 and NR2C in a model of gentamicin
nephrotoxicity.
Methods. Rats were exposed to either saline (control), high-
dose, short-term gentamicin, or short-term gentamicin plus the
NMDA antagonist MK-801 (short-term gentamicin + MK-801)
for 3 days.
Results. Real-time reverse transcription-polymerase chain
reaction (RT-PCR) revealed that NR1 mRNA expression was
significantly higher (P = 0.03) in the renal cortex of short-term
gentamicin rats. NR2C subunit mRNA expression was unal-
tered in short-term gentamicin rats. Western blot analysis re-
vealed that NR1 (P = 0.009) and NR2C (P = 0.003) protein
abundance was significantly higher in the renal cortex short-
term gentamicin rats. We assessed two potential intracellu-
lar pathways that may mediate short-term gentamicin/NMDA.
Calpain I and II expression was similar in short-term gentamicin
and control rats. Endothelin type B receptor (ETBR) expres-
sion was significantly increased in the renal cortex of short-term
gentamicin rats (P = 0.0003), and urinary nitrite concentration
(reflecting nitric oxide) was significantly increased in short-term
gentamicin rats (P = 0.03). Serum creatinine was significantly
elevated in short-term gentamicin animals (P = 0.03), and this
increase was attenuated in short-term gentamicin + MK-801
rats. Blood pressure was higher in short-term gentamicin rats;
this was attenuated in short-term gentamicin + MK-801 rats.
Urine pH was significantly lower in short-term gentamicin (P <
0.0001) rats; this was reversed in short-term gentamicin + MK-
801 (P = 0.005) rats. Urinary nitrite was significantly higher in
short-term gentamicin rats; this was normalized in short-term
gentamicin + MK-801 rats. MK-801 alone had no effect on clin-
ical parameters.
Conclusion. NMDA receptor subunit expression is increased
in short-term gentamicin animals, and the receptor likely medi-
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ates cell damage via the endothelin-ETBR-nitric oxide pathway.
NMDA antagonism ameliorated renal damage after exposure
to short-term gentamicin.
The strychnine-insensitive N-methyl-D-aspartate
(NMDA) receptor, part of the glutamate receptor family,
was originally identified in the central nervous system
(CNS). The receptor is linked to a calcium channel.
Its agonists include magnesium, D-serine, D-alanine,
and L-amino-cyclopropane carboxylic acid (ACPC).
The NMDA receptor is comprised of various subunits.
The main subunits are NR1, NR2A, NR2B, NR2C, and
NR2D. The NR1 subunit is the main subunit of the
NMDA receptor [1–3]. The NR1 subunit is essential
for channel activity whereas the NR2 subunits confer
modulatory properties [4].
The NMDA receptor is expressed outside the CNS. An-
tagonists to the NMDA receptor bind to various extra-
neuronal tissues, including the heart, stomach, pancreas,
and kidney [5]. Moreover, kidney tubules bind strychnine,
glycine, ACPC, D-alanine, and D-serine, all agonists of the
brain NMDA receptor [6]. Studies in our laboratory es-
tablished that the NR1 and NR2 subunits of the NMDA
receptor are expressed in the kidney, with very high ex-
pression in the proximal tubule [7]. Similarly, Deng et al
[8] showed NR1 is expressed in the kidney.
Gentamicin is part of the aminoglycoside family of
antibiotics that are effective against gram-negative organ-
isms. Their use is limited by ototoxicity [9] and nephro-
toxicity [10–12]. There are many factors that promote
gentamicin ototoxicity, including nitric oxide [13], calpain
[14], the c-jun N-terminal kinase (JNK) pathway [15],
brain-derived neurotrophic factor [16], oxidants [17], and
calcium influx [18]. The NMDA receptor also plays a
pivotal role in gentamicin ototoxicity [16, 19–21]. Fur-
thermore, gentamicin ototoxicity is ameliorated by an-
tagonists to the NMDA receptor [17, 19, 21].
There are several established mechanisms of gentam-
icin nephrotoxicity, including alteration of inositol phos-
pholipid distribution [22], lysosomal instability due to
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diminished activity of phospholipase A and C [23], and
mitochondrial swelling and dsyfunction due to influx of
cations [12]. In addition, gentamicin increases calcium in-
flux into cells and this buildup of calcium correlates with
cell damage [10].
Heretofore, the role of the NMDA receptor in the kid-
ney remained unclear. Based upon the prominent role
the receptor plays in gentamicin ototoxicity, the high ex-
pression of the NMDA receptor in the renal proximal
tubule, and the high degree of gentamicin toxicity in the
proximal tubule, we speculated that the NMDA receptor
might be activated by and may play a role in renal injury
caused by gentamicin.
METHODS
Real-time reverse transcription-polymerase chain
reaction (RT-PCR)
We used the Qiagen QuantiTectTM SYBR Green
RT-PCR method for quantitative, real-time one-step
RT-PCR (Qiagen Laboratories, Valencia, CA, USA).
Briefly, primers were designed of length 100 to 150 bp.
The primers chosen were NR1-NCBI accession number
X63255: sense, CGGGTASAACAACAGCAACAAA-
21 bp; antisense, ACAATCATGTCCGCTTGGC-19 bp;
and NR2C-NCBI accession number NM 010350:
sense, CCATCCTCAGCATCAGTG-18 bp; antisense,
CTCCAGCACCTTGAACAG-18 bp. After RNA
extraction, equal amounts of RNA were exposed to
DNAse treatment.
RNA was requantified. Then, equal amounts of RNA
were used for real-time RT-PCR. A 50 lL “master mix”
was prepared with the following reagents: 25 lL 2×
QuantiTect SYBR Green RT-PCR Master Mix (final con-
centration = 1×), 0.5 lmol/L sense and antisense primer,
0.5 lL QuantiTect RT Mix, 0.375 lg RNA, and RNAse-
free water to make a final reaction volume of 50 lL. Af-
ter an initial RT step of 30 minutes at 50◦C, the RNA
was exposed to an initial activation step of 15 minutes
at 95◦C. Then, we performed PCR with cycles as fol-
lows: 94◦C (denaturation) for 15 seconds, 50
◦
C to 60◦C
(annealing) for 30 seconds, and 72◦C (extension) for
30 seconds. We optimized the annealing time and the
number of cycles according to each primer pair. For each
sample, we ran two negative controls. In one, the RT
enzyme was eliminated (RT−), and in another, RNA
was substituted by water. For all samples, we performed
simultaneous real-time RT-PCR with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). All NMDA val-
ues were normalized for GAPDH. The samples were run
on a BioRad iCyclerTM and the data was analyzed by
the BioRad iCycleTM Program (BioRad, Hercules, CA,
USA). The calculated threshold (CT) was determined for
all samples, defined as the amount of the NR1 or NR2C
gene in relation to the reference gene, GAPDH. All
results are displayed as fold induction of target gene
mRNA expression as determined by the CT method.
Briefly, CT indicates the difference between the num-
ber of cycles necessary to detect the PCR products of
either NR1 or NR2C and the reference gene, GAPDH
[24]. All samples were run in duplicate and the overall
values were calculated from the mean of the duplicates.
Only samples with negative results for the RT− were in-
cluded for analysis [25].
Immunoprecipitation (NR1)
Affinity-purified antibody to NR1 (4 lg) was at-
tached to 30 lL of Gamma Bind–G Sepharose beads
(Amersham, Uppsala, Sweden) by incubating overnight
at 4◦C with gentle agitation, followed by washes in
a solution containing 250 mmol/L sucrose, 1 mmol/L
ethylenediaminetetraacetic acid (EDTA), 5 mmol/L Tris,
0.5 mmol/L benzamidine HCl, 1 lmol/L leupeptin,
1 lmol/L pepstatin A, and 0.3 mmol/L phenylmethyl-
sulfonyl fluoride (PMSF). Prior to incubation of protein
with NR1, the protein (0.5 mg) was incubated with pu-
rified mouse IgG1 (0.5 lg) (Becton Dickinson, San Jose,
CA, USA) to minimize nonspecific binding. The super-
natant from this reaction was captured and washed gen-
tly. The protein was then added to a tube containing the
beads coated with NR1 and the mixture was incubated for
1 hour at 4◦C with gentle agitation. Afterwards, the beads
were washed and resuspended in 30 lL 2× Laemmli
buffer. The samples were boiled and western blot analysis
was performed [7].
Western blot analysis
Samples containing 40 lg of protein were elec-
trophoretically separated and then transferred to
polyvinlidine difluoride (PVDF) membranes. Mem-
branes were incubated with the NMDA antibodies and
then exposed to a horseradish peroxidase (HRP)-linked
secondary antibody. The membranes was then processed
by enhanced chemiluminescence (ECL) PlusTM and ex-
posed to radiography. The NR1 antibody (added in
concentration 1:100) was a mouse antirat monoclonal
antibody obtained from Upstate Biotechnology (Lake
Placid, NY, USA). The size of the NR1 subunit protein
is 130 kD. The NR2C antibody (added in a concentration
1:200) was a goat antimouse polyclonal antibody obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
The size of the NR2C subunit protein was 149 kD [4].
Calpain I antibody (added in concentration 1:100) was
a rabbit antihuman polyclonal antibody obtained from
Santa Cruz Biotechnology. Calpain II antibody (added
in concentration 1:100) was a goat antihuman polyclonal
antibody obtained from Santa Cruz Biotechnology. En-
dothelin receptor type B (ETBR) antibody (added in
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concentration 1:100) was a goat antihuman polyclonal
antibody obtained from Santa Cruz Biotechnology.
Loading for NR1, which cannot be achieved by nor-
malization by GAPDH since it was passed through im-
munoprecipitation, was accomplished by normalization
to unbound IgG1 [26]. For each blot assessing the NR2C
antibody, loading was assessed by immunoblot with anti-
sera to a monoclonal mouse antirabbit antibody directed
against GAPDH (Research Diagnostic, Inc., Flanders,
NJ, USA). For GAPDH, the secondary IgG antibody was
linked to HRP and added at a concentration of 1:20,000.
Detection was achieved by use of ECL PlusTM [7].
Animals
All animals were purchased from Harlan Laborato-
ries (Indianapolis, IN, USA). All experiments were per-
formed on mature (225 to 250 g) male Sprague-Dawley
rats. Upon arrival to our facility, the animals were al-
lowed at least 72 hours to acclimate. During the study
period, all animals were given free access to standard
rat chow and water. The animals were housed in indi-
vidual metabolic cages to allow for collection of urine.
All animals were weighed prior to receiving treatment
and on the day of sacrifice. Urine was collected for
24 hours prior to the beginning of treatment and during
the final 24 hours of the 3-day treatment course. Animals
were given either high-dose gentamicin (Sigma, St. Louis,
MO, USA), 100 mg/kg/day, subcutaneously, for 3 consec-
utive days (short-term gentamicin) or the equal volume
of saline [27]. For some studies, a third group of animals
received 0.1 mg/kg/day of the NMDA antagonist MK-
801 [28] 30 minutes prior to receiving each daily dose
of short-term gentamicin (short-term gentamicin + MK-
801). Twenty-four hours after the final injection(s), rats
were anesthetized with 65 mg/kg pentobarbital intraperi-
toneally and sacrificed. The kidneys were excised and
either total kidney tissue was saved or the cortex was sep-
arated from the medulla. All tissues were rapidly placed
in a solution containing either RNAlaterTM for eventual
RNA extraction or in a solution for isolation of proteins:
250 mmol/L sucrose, 1 mmol/L EDTA, 5 mmol/L Tris,
0.5 mmol/L benzamidine HCl, 1 lmol/L leupeptin,
1 lmol/L pepstatin A, and 0.3 mmol/L PMSF [7].
Determination of serum creatinine
Serum was obtained from the rats prior to and 3 days
after the period of therapy. Measurement of serum crea-
tinine was according to established protocols.
Blood pressure measurements
Blood pressure measurements were assessed by the
tail-cuff method using a photoelectric sensor system [29]
(ITC, Woodland Hills, CA, USA). For acclimation, each
animal had several blood pressures measured 1 day prior
to the actual recordings. Measurements were taken 1 day
prior to the administration of either the vehicle, short-
term gentamicin, or short-term gentamicin + MK-801,
and then on the day of sacrifice.
Urine pH
Urine pH was assessed by established techniques (dip-
stick analysis).
Measurement of urinary nitric oxide
The sum of urine nitrite and nitrate, an index of ni-
tric oxide production, was determined spectrophotomet-
rically as nitrite after conversion of nitrate to nitrite by the
Griess reaction (R&D Systems, Minneapolis, MN, USA).
Statistical analysis
Densitometric values from scanned immunoblots were
determined and the data are expressed as mean ± SE,
Differences between two groups were assessed by the
Student t test. Differences among >two groups was as-
sessed by one-way analysis of variance (ANOVA) with
Bonferroni’s multiple comparison test. Significance is de-
fined as P < 0.05.
RESULTS
Renal NMDA subunit mRNA expression in
short-term gentamicin
We measured NR1 and NR2C subunit mRNA expres-
sion in the total kidney, renal cortex, and renal medulla
by real-time RT-PCR. As described previously [24, 25],
the data for real-time RT-PCR is expressed as the fold
change induction of gene expression in the target tissue
(short-term gentamicin) compared to the standard (con-
trol) tissue, both of which are normalized by GAPDH.
Thus, for comparison, the control tissue gene expression
is displayed as 1.0. Although standard deviation is not
displayed in the figures for the control, the fold induction
of gene expression in the experimental tissue (short-term
gentamicin) is calculated based upon the mean ± SD of
all control and experimental samples.
NR1 subunit mRNA expression was significantly
higher (1.68-fold, P = 0.03) in the renal cortex of short-
term gentamicin versus control animals. NR1 mRNA ex-
pression was 1.38 fold higher in the total kidney obtained
from short-term gentamicin versus control animals, but
this did not reach statistical significance (P = 0.5). NR1
mRNA expression was virtually identical in the renal
medulla isolated from short-term gentamicin and control
animals (P = 0.9) (Fig. 1). NR2C subunit mRNA expres-
sion was similar in the total kidney (P = 0.9), renal cor-
tex (P = 0.2), and renal medulla (P = 0.9) of short-term
gentamicin versus control animals (Fig. 2). As displayed,
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Fig. 1. NR1 mRNA expression in renal cortex as determined by real-
time reverse transcription-polymerase chain reaction (RT-PCR). Data
are expressed as the fold change induction of gene expression in the
target tissue short-term gentamicin (STG) compared to the standard
(control) tissue, both of which are normalized by glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). For comparison, the control tis-
sue gene expression is thus 1.0. Although standard deviation is not
shown for the control, the fold induction of gene expression in the ex-
perimental tissue (short-term gentamicin) is calculated based upon the
mean ± SD of all control and experimental samples. Based upon the
fold change, in NR1 mRNA expression is significantly higher in the re-
nal cortex (B) (P = 0.03), and similar in the total kidney (A) and renal
medulla (C) of short-term gentamicin versus control rats (N = 4).
there was some variability in NR2C mRNA expression,
but the mean values were very similar.
NMDA subunit protein abundance in kidneys of
control and short-term gentamicin animals
We used immunoprecipitation and subsequent west-
ern blot analysis to assess NR1 abundance. Since val-
ues for immunoprecipitation cannot be standardized by
GAPDH as is performed for other proteins, NR1 values
were normalized by simultaneous measurement of IgG1
for each blot, as previously described [26]. NR1 subunit
protein abundance was significantly higher (P = 0.009)
in the renal cortex of short-term gentamicin versus con-
trol animals. NR1 protein abundance was similar in the
total kidney (P = 0.6) and in the renal medulla (P = 0.3)
isolated from short-term gentamicin and control animals
(Fig. 3).
NR2C subunit protein abundance (normalized by
GAPDH) was significantly higher (P = 0.003) in the renal
cortex of short-term gentamicin versus control animals.
NR2C protein abundance was similar in the total kidney
(P = 0.8) and in the renal medulla (P = 0.7) from short-
term gentamicin and control animals (Fig. 4).
Intracellular pathways generated by short-term
gentamicin/NMDA
We assessed two potential pathways that may be ac-
tivated by short-term gentamicin/NMDA in the kidney.
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Fig. 2. NR2C mRNA expression in renal cortex as determined by real-
time reverse transcription-polymerase chain reaction (RT-PCR). Data
are expressed as the fold change induction of gene expression in the
target tissue short-term gentamicin (STG) compared to the standard
(control) tissue, both of which are normalized by glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). For comparison, the control tis-
sue gene expression is thus 1.0. Although standard deviation is not
shown for the control, the fold-induction of gene expression in the ex-
perimental tissue (short-term gentamicin) is calculated based upon the
mean ± SD of all control and experimental samples. Based upon the
fold change, NR2C mRNA expression is similar in the total kidney
(A), renal cortex (B), and renal medulla (C) isolated from control and
short-term gentamicin rats (N = 4).
First, we assessed the calpain pathway. Calpain is a
calcium-activated protease that is stimulated by short-
term gentamicin/NMDA in the CNS and plays a major
role in gentamicin ototoxicity [16, 19–21]. Additionally,
calpain is activated in renal models of cell injury [30].
Calpain I (P = 0.8) and calpain II (P = 0.4) protein
abundance were similar in the renal cortex of control and
short-term gentamicin rats (Fig. 5).
We also assessed the ETBR-nitric oxide pathway,
which has been speculated to mediate cell injury in-
duced by various nephrotoxicants [31]. Our data show
that ETBR protein abundance was significantly higher in
the renal cortex of short-term gentamicin versus control
rats (P = 0.0003) (Fig. 6). To measure urinary nitric ox-
ide excretion, we assessed the conversion of nitrite from
nitrates by the Griess reaction. Both urinary nitrite con-
centration (P = 0.03) and total nitrite excretion/day (P =
0.01) were significantly higher in short-term gentamicin
versus control rats (Fig. 7).
Effect of NMDA antagonist on clinical parameters
after short-term gentamicin
For these studies, we included three groups of an-
imals: animals receiving the vehicle (control), those
receiving short-term gentamicin, and those receiving
short-term gentamicin plus the NMDA antagonist MK-
801 (short-term gentamicin + MK-801). Prior to the study
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Fig. 3. NR1 protein abundance (corrected by IgG1) in total kidney
tissue (A) tissue, renal cortex (B), renal medulla (C) obtained from
control and short-term gentamicin (STG) rats, as determined by West-
ern blot analysis. NR1 protein abundance is significantly higher in the
renal cortex of short-term gentamicin versus control rats (P = 0.009).
NR1 protein abundance is similar in total kidney and renal medulla
tissue in control and short-term gentamicin rats (N = 4).
period, serum creatinine was similar in all groups (data
not shown). Analysis by one-way ANOVA revealed that
although the serum creatinine was higher in short-term
gentamicin (0.84 ± 0.05 mg/dL) versus control (0.72 ±
0.03 mg/dL) rats with normalization in rats exposed to
short-term gentamicin + MK-801 (0.70 ± 0.05 mg/dL),
this did not reach statistical significance (P = 0.07). The
minor changes in serum creatinine we observed are sim-
ilar to various other studies using this model [32–34],
consistent with mainly tubular damage after short-term
gentamicin. Systolic and diastolic blood pressures were
similar in all groups prior to the study period (data not
shown). Analysis by one-way ANOVA revealed that
post-treatment systolic blood pressure was significantly
higher in short-term gentamicin (122.8 ± 3.7 mm Hg)
compared to control (107.8 ± 4.9 mm Hg; P = 0.02) ani-
mals, and this increase was attenuated in short-term gen-
tamicin + MK-801 (113.8 ± 4.1 mm Hg) rats, although
this did not reach statistical significance (P = 0.1 ver-
sus short-term gentamicin). Systolic blood pressure was
similar in control and short-term gentamicin + MK-801
rats (P = 0.4). Analysis by one-way ANOVA revealed
that post-treatment diastolic blood pressure was signif-
icantly higher in short-term gentamicin (78.1 ± 4.6 mm
Hg) versus either control (64.6 ± 3.8 mm Hg) (P = 0.04)
or MK-801 (66.8 ± 1.7 mm Hg) (P = 0.04) rats. Post-
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Fig. 4. NR2C protein abundance [corrected by glyceraldehyde-3-
phosphate dehydrogenase (GAPDH)] in total kidney tissue (A) tissue,
renal cortex (B), renal medulla (C) obtained from control and short-
term gentamicin (STG) rats, as determined by Western blot analysis.
NR2C protein abundance is significantly higher in the renal cortex of
short-term gentamicin versus control rats (P = 0.003). NR2C protein
abundance is similar in total kidney and renal medulla tissue in control
and short-term gentamicin rats (N = 4).
treatment diastolic blood pressure was similar in con-
trol versus short-term gentamicin + MK-801 (P = 0.6)
rats. Analysis by one-way ANOVA revealed that urine
pH, which has previously been shown to be reduced af-
ter exposure of rats to high-dose gentamicin [32], was
lower in short-term gentamicin (6.4 ± 0.1) versus control
(7.9 ± 0.2) (P < 0.0001) rats, presumably reflecting re-
nal compensation for retention of acid. The low urine pH
was attenuated in short-term gentamicin + MK-801 rats
(7.0 ± 0.2) (P = 0.005 versus short-term gentamicin)
(Fig. 8).
Effect of NMDA antagonist on urinary nitrite after
short-term gentamicin
Urinary nitrite concentration and nitrite excretion/day
were significantly higher in short-term gentamicin versus
control or short-term gentamicin + MK-801 rats. Specif-
ically, urinary nitrite concentration was higher in short-
term gentamicin (1089.0 ± 252.0 lmol/L) versus either
control (376.2 ± 123.6 lmol/L) (P = 0.03) or short-term
gentamicin + MK-801 (429.5 ± 45.6 lmol/L) (P = 0.04)
rats. Urinary nitrite concentration was similar in con-
trol versus short-term gentamicin + MK-801 (P = 0.7)
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Fig. 5. Calpain-I (A) and calpain-II (B) protein abundance in the renal
cortex of rats treated with 3 days of high-dose gentamicin. Calpain I and
calpain II expression is similar in control and short-term gentamicin
(STG) rats (N = 8).
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Fig. 6. Endothelin type B receptor (ETBR) protein abundance in
the renal cortex of rats treated with 3 days of high-dose gentam-
icin. ETBR expression is increased in the renal cortex of kidneys ob-
tained from rats exposed to short-term gentamicin (STG). ∗P = 0.0003
(N = 8).
rats. Urinary nitrite excretion/day was significantly higher
in short-term gentamicin (12.0 ± 2.3 lmol/day) versus
control (4.0 ± 1.7 lmol/day) (P = 0.01) or short-term
gentamicin + MK-801 (1.9 ± 0.4 lmol/day) (P = 0.001)
rats. Nitrite excretion/day was similar in control versus
short-term gentamicin + MK-801 (P = 0.3) rats (Fig. 9).
Renal histology in short-term gentamicin
We performed light microscopy on tissue obtained
from all three groups of animals. Exposure to short-term
gentamicin induced significant cellular damage as evi-
denced by tubular necrosis and widespread vacuoliza-
tion. These changes were absent in kidneys obtained from
both control and short-term gentamicin + MK-801 rats
(Fig. 10).
Effect of NMDA antagonist in rats
Recent data presented by Deng et al [8] suggest that
acute exposure of rats to MK-801 results in alterations
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Fig. 7. Urinary nitrite in rats treated with short-term gentamicin
(STG). Pretreatment urinary nitrite was similar in all groups (data not
shown). (A) Posttreatment urine nitrite concentration and (B) total
nitrite excretion/day was significantly higher (P = 0.03, P = 0.01, re-
spectively) in animals exposed to short-term gentamicin compared to
control animals (N = 8).
in renal blood flow and glomerular filtration rate. There-
fore, since it is plausible that rats exposed to short-term
gentamicin plus the NMDA antagonist MK-801 may have
exhibited protection from renal damage by an unrelated
hemodynamic mechanism, we assessed renal function in
rats exposed to either the vehicle or MK-801 alone for 3
consecutive days. These results are displayed in Figure 11.
Systolic blood pressure (P = 0.8), diastolic blood pres-
sure (P = 0.6), serum creatinine (P = 0.3), and urine pH
(P = 0.8) were similar in both groups of rats. These results
indicate that the protective effect of MK-801 in rats ex-
posed to short-term gentamicin is not due to an unrelated
hemodynamic effect of the receptor antagonist but most
likely due to direct antagonism of the receptor at the re-
nal tubular cellular level. Urine nitrite excretion per day
was similar (P = 0.8) in both groups of rats.
DISCUSSION
Gentamicin is part of the aminoglycoside family of an-
tibiotics that are commonly used to inhibit the growth
of gram-negative bacteria. Unfortunately, the use of
gentamicin is limited by the risk of ototoxicity and
Leung et al: Altered NMDA receptor expression in renal toxicity 173
0.0
0.2
0.4
0.6
0.8
1.0
Se
ru
m
 c
re
at
in
in
e,
m
g/
dL
Co
ntr
ol
ST
G
ST
G +
MK
-80
1
Co
ntr
ol
ST
G
ST
G +
MK
-80
1
100
110
120
130
SB
P,
 
m
m
 H
g
*
Co
ntr
ol
ST
G
ST
G +
MK
-80
1
60
70
80
90
D
BP
,
 
m
m
 H
g *
Co
ntr
ol
ST
G
ST
G +
MK
-80
1
5
6
7
8
9
Ur
in
e 
pH
*
Fig. 8. Clinical parameters in short-term gentamicin (STG). Posttreat-
ment systolic blood pressure was significantly higher in short-term
gentamicin versus control animals (∗P = 0.02). Posttreatment systolic
blood pressure was higher in rats exposed to short-term gentamicin
compared to short-term gentamicin + MK-801. Posttreatment diastolic
blood pressure was significantly higher in short-term gentamicin ver-
sus control (∗P = 0.04) and short-term gentamicin + MK-801 animals
(∗P = 0.04). Serum creatinine was slightly higher in short-term gen-
tamicin versus control or short-term gentamicin + MK-801 rats and
is similar in control versus short-term gentamicin + MK-801 animals.
Posttreatment urine pH was significantly lower in short-term gentam-
icin versus control animals (∗P < 0.0001), and also significantly lower in
short-term gentamicin animals versus short-term gentamicin + MK-801
animals (∗P = 0.005), and similar in control versus short-term gentam-
icin + MK-801 animals (N = 8).
nephrotoxicity. In general, ototoxicity is not reversible
and may result in permanent and severe hearing loss. Al-
though the renal damage may be self-limited, there may
be severe and permanent renal impairment [10–12, 35,
36]. The spectrum of biochemical and physiologic renal
abnormalities includes reduction in glomerular filtration
rate due to glomerular damage, and hypomagnesemia,
hypokalemia, and hypocalcemia due to tubular damage.
The renal damage due to gentamicin is primarily due to
the accumulation of the drug within the renal cortex.
Indeed, aminoglycosides are preferentially reabsorbed
by the proximal tubule cells, owing to a higher extent
of damage in that nephron segment. Nevertheless, the
distal tubule may also exhibit damage from aminoglyco-
sides [37].
There are many studies exploring the mechanisms
of gentamicin-induced nephrotoxicity. Generally, it is
agreed that uptake of gentamicin into the proximal
tubule cells is mediated in part by polyanionic inositol
phospholipids [22] or megalin [27]. After entry into the
proximal tubule cell and endocytosis, aminoglycosides
accumulate in lysosomes, which eventually swell and
through a series of events induce cell damage [34].
What has been controversial is whether there are other
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Fig. 9. Effect of N-methyl-D-aspartate (NMDA) antagonist on urine
nitrite in short-term gentamicin (STG). Urine nitrite in short-term gen-
tamicin. Pretreatment urine nitrite concentration and excretion/day was
similar in all three groups. Posttreatment concentration (A) was sig-
nificantly lower in short-term gentamicin versus control animals (P =
0.03), and also significantly lower in short-term gentamicin animals ver-
sus short-term gentamicin + MK-801 animals (P = 0.04), and similar in
control versus short-term gentamicin + MK-801 animals. Posttreatment
nitrite excretion/day (B) was significantly lower in short-term gentam-
icin versus control animals (P = 0.01), and also significantly lower in
short-term gentamicin animals versus short-term gentamicin + MK-801
animals (P = 0.001), and similar in control versus short-term gentamicin
+ MK-801 animals (N = 8).
mechanisms by which aminoglycosides may enter into
the proximal tubule cell. Recent studies by Girton,
Sundin, and Rosenberg [35] strongly suggest that there
is a phospholipid- and megalin-independent pathway of
aminoglycoside uptake into the renal cell.
We assessed the role of the NMDA receptor in gentam-
icin nephrotoxicity based upon its role in ototoxicity and
the role of calcium influx in aminoglycoside nephrotoxi-
city [10]. Our results show that the mRNA expression of
the main NMDA subunit, NR1, is significantly increased
in short-term gentamicin rats within the renal cortex, the
main site of gentamicin uptake in the kidney. NR1 pro-
tein abundance was also significantly higher in the renal
cortex of short-term gentamicin rats versus the controls,
and was similar in the total kidney and renal medulla
in the two groups. Therefore, although we cannot rule
out posttranscriptional regulation of NR1 in short-term
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Fig. 10. Renal morphology in short-term
gentamicin (STG). Rats exposed to short-
term gentamicin exhibited proximal and distal
tubule damage, as evidenced by nuclear en-
largement (black arrows), congestion, tubular
necrosis, polychromasia, epithelial flattening,
and vacuolization (white arrows) (A) (10×)
and (B) (40×). Rats exposed to either the
control (C) (10×) and (D) (40×) or short-
term gentamicin + MK-801 (E) (10×) and
(F) (40×) displayed normal renal morphology
(N = 4).
gentamicin nephrotoxicity, the enhanced expression of
NR1 appears to be at least transcriptionally mediated.
We also assessed the expression and abundance of the
other renal NMDA subunit, NR2C, in this model of gen-
tamicin toxicity. NR2C is not the main subunit of the
receptor and NR2 subunits alone cannot form a chan-
nel. However, the NR2 subunits can confer modulatory
properties on the receptor [4]. NR2C protein abundance
was significantly higher in the renal cortex of short-term
gentamicin rats versus the controls, although NR2C
mRNA expression in the renal cortex was similar in the
two groups, suggesting posttranscriptional regulation.
We then performed studies to explore the potential
intracellular pathways generated by short-term gentam-
icin/NMDA. First, we evaluated a pathway involving
calpain, a calcium-activated protease that is activated by
short-term gentamicin in the ear, resulting in ototoxic-
ity [38]. Moreover, after hypoxia to the proximal tubule,
there is activation of calpain, causing cell death [30]. The
protein abundance of the two calpain isoforms (I and
II) was unaltered by short-term gentamicin. We then
assessed a pathway involving ETRB, and nitric oxide.
There is evidence to suggest that this pathway may be
activated by short-term gentamicin in the kidney. First,
gentamicin-induced reactive oxygen species are inhibited
by the nitric oxide inhibitor L-NAME [39]. Furthermore,
aminoglycosides stimulate endothelin-1 (ET-1) and sub-
sequently nitric oxide in renal proximal tubules, an effect
inhibited by L-NAME [31]. Moreover, oral L-arginine
protects rats against gentamicin-induced renal failure
in rats. Finally, gentamicin induces mesangial cell in-
ducible nitric oxide synthase (iNOS)/nitric oxide produc-
tion, an effect blocked by L-NAME [40]. Our results show
that ETRB protein abundance is increased in the renal
cortex of rats exposed to short-term gentamicin. In addi-
tion, urinary nitrite (reflecting nitric oxide) concentration
and excretion/day is markedly increased in rats exposed
to short-term gentamicin. Thus, there is evidence that
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Fig. 11. Clinical parameters in animals exposed to MK-801. Systolic
blood pressure (SBP) (A), diastolic blood pressure (DBP) (B), serum
creatinine (C), urine pH (D), and urine nitrite excretion per day (E)
were similar in control and MK-801 rats (N = 4).
this pathway is activated by short-term gentamicin, and
possibly, mediated by the NMDA receptor. It remains
unclear how aminoglycosides stimulate calcium entry
into the cell and subsequently induce this pathway. We
speculate that calcium enters into the cell via the NMDA
receptor.
To study whether blockage of the NMDA receptor may
attenuate renal damage in rats exposed to short-term
gentamicin, we exposed rats to the vehicle, short-term
gentamicin, or short-term gentamicin plus the NMDA
receptor antagonist MK-801 and assessed glomerular and
tubular function. Our results show that rats exposed to
short-term gentamicin experience a significant increase in
serum creatinine, which was attenuated in rats exposed
to short-term gentamicin + MK-801. Although the per-
cent rise in serum creatinine in short-term gentamicin rats
was relatively modest, it needs to be stated that the per-
cent change in serum creatinine does vary in this model
[32–34]. Urine pH was markedly lower in short-term gen-
tamicin versus control and short-term gentamicin + MK-
801 rats. The decrease in urine pH has been observed
before after exposure to short-term gentamicin [32], and
this may reflect an attempt by the renal tubule to compen-
sate for an acidotic state by increasing secretion of acid
into the urine. The decrease in urine pH was attenuated in
rats exposed to short-term gentamicin + MK-801. Prior
studies show that rats exposed to short-term gentamicin
experience an increase in blood pressure [33]. Our results
confirm this finding. Furthermore, the increase in systolic
blood pressure and diastolic blood pressure was amelio-
rated in rats exposed to short-term gentamicin+MK-801.
Finally, based upon prior studies showing nitric oxide ac-
tivation in short-term gentamicin [31, 39, 40], we assessed
urinary nitric oxide excretion in our model of short-term
gentamicin. Our results show that urinary nitric oxide was
dramatically increased in short-term gentamicin rats. This
effect was completely reversed in rats exposed to short-
term gentamicin + MK-801. Taken together, these studies
show that glomerular and tubular damage after exposure
to short-term gentamicin is ameliorated by pretreatment
with the NMDA receptor blocker MK-801, further sug-
gesting a definitive role for the NMDA receptor in this
model of renal toxicity.
Our last group of experiments was designed to explore
if MK-801 alone may have affected clinical parameters
even in the absence of NMDA blockade. In these experi-
ments, we assessed renal function in rats exposed to either
the vehicle or MK-801 alone for 3 consecutive days. Clin-
ical parameters in rats exposed to MK-801 were similar
to control rats, suggesting that the restoration of normal
clinical parameters in rats exposed to short-term gentam-
icin plus MK-801 is probably due to direct antagonism of
NMDA receptors located on the renal tubular cell and
not an unrelated hemodynamic effect.
CONCLUSION
We have shown that in a rat model of short-term, high-
dose gentamicin nephrotoxicity, there is increased ex-
pression of both renal NMDA subunits, NR1 and NR2C.
We speculate that following glomerular filtration of gen-
tamicin, the drug interacts with the NMDA receptor,
stimulating entry of calcium into the cell through the
NMDA calcium channel. Thereafter, our results sug-
gest that an intracellular pathway involving endothelin,
ETRB, and nitric oxide is activated. Finally, the ame-
lioration of renal damage in rats exposed to short-term
gentamicin that are pretreated with the NMDA receptor
blocker MK-801 provides further proof of the important
role of this receptor in this model of renal toxicity.
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